WNT Signaling Cascade Proteins and LRP6 in the Formation of Various Types of Coronary Lesions in Patients With Coronary Artery Disease

Aim. Assessment of WNT1, WNT3a, and LRP6 concentrations in patients with ischemic heart disease (IHD) and obstructive and non-obstructive coronary artery (CA) disease.

Material and methods. This cross-sectional observational study included 50 IHD patients (verified by coronary angiography, CAG), of which 25 (50%) were men, mean age 64.9±8.1 years; 20 patients had non-obstructive CA disease (stenosis <50%), and 30 patients had hemodynamically significant stenosis. Concentrations of WNT1, WNT3a and LRP6 were measured in all patients.

Results. The concentrations of WNT1 and WNT3a proteins were significantly higher in patients with IHD and obstructive CA disease (p < 0.001), while the concentration of LRP6 was higher in the group with non-obstructive CA disease (p = 0.016). Data analysis of the group with obstructive CA disease showed a moderate correlation between WNT1 and LRP6 (ρ=0.374; p=0.042). Correlation analysis of all groups of patients with CA disease revealed a moderate association between the concentrations of WNT1 and uric acid (ρ=0.416; p=0.007). Regression analysis showed that risk factors for the development of IHD, such as increased body mass index, age, smoking, dyslipidemia, and hypertension, did not significantly influence the type of CA disease in IHD patients. According to ROC analysis, the obstructive form of IHD was predicted by a WNT3a concentration higher than 0.155 ng/ml and a LRP6 concentration lower than 12.94 ng/ml.

Conclusion. IHD patients with non-obstructive CA disease had the greatest increase in LRP6, while patients with obstructive CA disease had significantly higher concentrations of the canonical WNT cascade proteins, WNT1 and WNT3a. According to the ROC analysis, a WNT3a concentration >0.155 ng/ml can serve as a predictor for the presence of hemodynamically significant CA stenosis in IHD patients (sensitivity 96.7%; specificity 70%), whereas a LRP6 concentration >12.94 ng/ml can predict the development of non-obstructive CA disease (sensitivity 76.7%; specificity 65%).

1. World Health Organisation. The top 10 causes of death. [Internet] Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death

2. Luengo-Fernandez R, Walli-Attaei M, Gray A, Torbica A, Maggioni AP, Huculeci R et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. European Heart Journal. 2023;44(45):4752–67. DOI: 10.1093/eurheartj/ehad583

3. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. European Heart Journal. 2020;41(37):3504–20. DOI: 10.1093/eurheartj/ehaa503

4. Braga JR, Austin PC, Ross HJ, Tu JV, Lee DS. Importance of Nonobstructive Coronary Artery Disease in the Prognosis of Patients With Heart Failure. JACC: Heart Failure. 2019;7(6):493–501. DOI: 10.1016/j.jchf.2019.02.014

5. Foulquier S, Daskalopoulos EP, Lluri G, Hermans KCM, Deb A, Blankesteijn WM. WNT Signaling in Cardiac and Vascular Disease. Pharmacological Reviews. 2018;70(1):68–141. DOI: 10.1124/pr.117.013896

6. Nusse R, Varmus H. Three decades of Wnts: a personal perspective on how a scientific field developed: Three decades of Wnts: a personal perspective. The EMBO Journal. 2012;31(12):2670–84. DOI: 10.1038/emboj.2012.146

7. Kusserow A, Pang K, Sturm C, Hrouda M, Lentfer J, Schmidt HA et al. Unexpected complexity of the Wnt gene family in a sea anemone. Nature. 2005;433(7022):156–60. DOI: 10.1038/nature03158

8. Schulte G. International Union of Basic and Clinical Pharmacology. LXXX. The Class Frizzled Receptors. Pharmacological Reviews. 2010;62(4):632–67. DOI: 10.1124/pr.110.002931

9. Wiese KE, Nusse R, Van Amerongen R. Wnt signalling: conquering complexity. Development. 2018;145(12):dev165902. DOI: 10.1242/dev.165902

10. Chen S, Bubeck D, MacDonald BT, Liang W-X, Mao J-H, Malinauskas T et al. Structural and Functional Studies of LRP6 Ectodomain Reveal a Platform for Wnt Signaling. Developmental Cell. 2011;21(5):848–61. DOI: 10.1016/j.devcel.2011.09.007

11. Green J, Nusse R, Van Amerongen R. The Role of Ryk and Ror Receptor Tyrosine Kinases in Wnt Signal Transduction. Cold Spring Harbor Perspectives in Biology. 2014;6(2):a009175. DOI: 10.1101/cshperspect.a009175

12. Clevers H, Nusse R. Wnt/β-Catenin Signaling and Disease. Cell. 2012;149(6):1192–205. DOI: 10.1016/j.cell.2012.05.012

13. Singh R, De Aguiar RB, Naik S, Mani S, Ostadsharif K, Wencker D et al. LRP6 Enhances Glucose Metabolism by Promoting TCF7L2Dependent Insulin Receptor Expression and IGF Receptor Stabilization in Humans. Cell Metabolism. 2013;17(2):197–209. DOI: 10.1016/j.cmet.2013.01.009

14. Keramati AR, Singh R, Lin A, Faramarzi S, Ye Z, Mane S et al. Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation. Proceedings of the National Academy of Sciences. 2011;108(5):1914–8. DOI: 10.1073/pnas.1019443108

15. Srivastava R, Zhang J, Go G, Narayanan A, Nottoli TP, Mani A. Impaired LRP6-TCF7L2 Activity Enhances Smooth Muscle Cell Plasticity and Causes Coronary Artery Disease. Cell Reports. 2015;13(4):746–59. DOI: 10.1016/j.celrep.2015.09.028

16. Ye Z, Go G-W, Singh R, Liu W, Keramati AR, Mani A. LRP6 Protein Regulates Low Density Lipoprotein (LDL) Receptor-mediated LDL Uptake. Journal of Biological Chemistry. 2012;287(2):1335–44. DOI: 10.1074/jbc.M111.295287

17. Mani A, Radhakrishnan J, Wang H, Mani A, Mani M-A, Nelson-Williams C et al. LRP6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors. Science. 2007;315(5816):1278–82. DOI: 10.1126/science.1136370

18. Raines EW. PDGF and cardiovascular disease. Cytokine & Growth Factor Reviews. 2004;15(4):237–54. DOI: 10.1016/j.cytogfr.2004.03.004

19. Shaw LJ, Shaw RE, Merz CNB, Brindis RG, Klein LW, Nallamothu B et al. Impact of Ethnicity and Gender Differences on Angiographic Coronary Artery Disease Prevalence and In-Hospital Mortality in the American College of Cardiology–National Cardiovascular Data Registry. Circulation. 2008;117(14):1787–801. DOI: 10.1161/CIR-CULATIONAHA.107.726562

20. Shaw LJ, Merz CNB, Pepine CJ, Reis SE, Bittner V, Kip KE et al. The Economic Burden of Angina in Women With Suspected Ischemic Heart Disease: Results From the National Institutes of Health–National Heart, Lung, and Blood Institute–Sponsored Women’s Ischemia Syndrome Evaluation. Circulation. 2006;114(9):894–904. DOI: 10.1161/CIRCULATIONAHA.105.609990

21. Manolagas SC, Almeida M. Gone with the Wnts: β-Catenin, T-Cell Factor, Forkhead Box O, and Oxidative Stress in Age-Dependent Diseases of Bone, Lipid, and Glucose Metabolism. Molecular Endocrinology. 2007;21(11):2605–14. DOI: 10.1210/me.2007-0259

22. Niehrs C. The complex world of WNT receptor signalling. Nature Reviews Molecular Cell Biology. 2012;13(12):767–79. DOI: 10.1038/nrm3470

23. Wang T, Sun C, Hu L, Gao E, Li C, Wang H et al. Sirt6 stabilizes athero sclerosis plaques by promoting macrophage autophagy and reducing contact with endothelial cells. Biochemistry and Cell Biology. 2020;98(2):120–9. DOI: 10.1139/bcb-2019-0057

24. Brown BA, Connolly GM, Mill CEJ, Williams H, Angelini GD, Johnson JL et al. Aging differentially modulates the Wnt pro‐survival signalling pathways in vascular smooth muscle cells. Aging Cell. 2019;18(1):e12844. DOI: 10.1111/acel.12844

25. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleveland Clinic Journal of Medicine. 2008;75(Suppl 5):S13–6. DOI: 10.3949/ccjm.75.Suppl_5.S13

26. Zhao J, Chen H, Liu N, Chen J, Gu Y, Chen J et al. Role of Hyperhomocysteinemia and Hyperuricemia in Pathogenesis of Atherosclerosis. Journal of Stroke and Cerebrovascular Diseases. 2017;26(12):2695–9. DOI: 10.1016/j.jstrokecerebrovasdis.2016.10.012

27. Mineo C. Lipoprotein receptor signalling in atherosclerosis. Cardiovascular Research. 2020;116(7):1254–74. DOI: 10.1093/cvr/cvz338